CompletedPhase 2NCT03638908

Fluoxetine in Pulmonary Arterial Hypertension (PAH) Trial

Studying Drug- or toxin-induced pulmonary arterial hypertension

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
University of Texas Southwestern Medical Center
Principal Investigator
Kelly Chin, MD
University of Texas Southwestern Medical Center
Intervention
Fluoxetine(drug)
Enrollment
8 enrolled
Eligibility
16-80 years · All sexes
Timeline
20132018

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03638908 on ClinicalTrials.gov

Other trials for Drug- or toxin-induced pulmonary arterial hypertension

Additional recruiting or active studies for the same condition.

See all trials for Drug- or toxin-induced pulmonary arterial hypertension

← Back to all trials